Transcriptional responses in Parascaris univalens after in vitro exposure to ivermectin, pyrantel citrate and thiabendazole by Martin, Frida et al.
Martin et al. Parasites Vectors          (2020) 13:342  
https://doi.org/10.1186/s13071-020-04212-0
RESEARCH
Transcriptional responses in Parascaris 
univalens after in vitro exposure to ivermectin, 
pyrantel citrate and thiabendazole
Frida Martin1* , Faruk Dube1, Oskar Karlsson Lindsjö2, Matthías Eydal3, Johan Höglund1, Tomas F. Bergström4 
and Eva Tydén1
Abstract 
Background: Parascaris univalens is a pathogenic parasite of foals and yearlings worldwide. In recent years, Parascaris 
spp. worms have developed resistance to several of the commonly used anthelmintics, though currently the mecha-
nisms behind this development are unknown. The aim of this study was to investigate the transcriptional responses 
in adult P. univalens worms after in vitro exposure to different concentrations of three anthelmintic drugs, focusing on 
drug targets and drug metabolising pathways.
Methods: Adult worms were collected from the intestines of two foals at slaughter. The foals were naturally infected 
and had never been treated with anthelmintics. Worms were incubated in cell culture media containing different 
concentrations of either ivermectin  (10−9 M,  10−11 M,  10−13 M), pyrantel citrate  (10−6 M,  10−8 M,  10−10 M), thiaben-
dazole  (10−5 M,  10−7 M,  10−9 M) or without anthelmintics (control) at 37 °C for 24 h. After incubation, the viability 
of the worms was assessed and RNA extracted from the anterior region of 36 worms and sequenced on an Illumina 
NovaSeq 6000 system.
Results: All worms were alive at the end of the incubation but showed varying degrees of viability depending on the 
drug and concentration used. Differential expression (Padj < 0.05 and log2 fold change ≥ 1 or ≤ − 1) analysis showed 
similarities and differences in the transcriptional response after exposure to the different drug classes. Candidate 
genes upregulated or downregulated in drug exposed worms include members of the phase I metabolic pathway 
short-chain dehydrogenase/reductase superfamily (SDR), flavin containing monooxygenase superfamily (FMO) and 
cytochrome P450-family (CYP), as well as members of the membrane transporters major facilitator superfamily (MFS) 
and solute carrier superfamily (SLC). Generally, different targets of the anthelmintics used were found to be upregu-
lated and downregulated in an unspecific pattern after drug exposure, apart from the GABA receptor subunit lgc-37, 
which was upregulated only in worms exposed to  10−9 M of ivermectin.
Conclusions: To our knowledge, this is the first time the expression of lgc-37 and members of the FMO, SDR, MFS 
and SLC superfamilies have been described in P. univalens and future work should be focused on characterising these 
candidate genes to further explore their potential involvement in drug metabolism and anthelmintic resistance.
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Background
Nematodes within the genus Parascaris are pathogenic 
parasites of foals and yearlings worldwide. Traditionally 
the parasite has been referred to as Parascaris equorum 
but recent cytological studies have established that the 
major species currently infecting horses in the USA and 
Europe is Parascaris univalens [1–3]. Parascaris spp. 
infection causes nasal discharge, coughing and impaired 
growth, while large burdens can be lethal due to obstruc-
tion and perforation of the small intestine [4, 5]. To avoid 
parasite-related disease, most foals are usually treated 
with anthelmintics from the drug classes macrocy-
clic lactones, benzimidazoles or tetrahydropyrimidines 
several times during the first year [6]. Macrocyclic lac-
tones act by binding to parasite-specific glutamate- and 
γ-aminobutyric acid (GABA) gated ion channels in nerve 
and muscle cells, increasing the cells permeability to  Cl- 
ions and leading to hyperpolarization which results in 
paralysis of the parasite [7]. Benzimidazoles bind parasite 
β-tubulin molecules, thereby disrupting the polymerisa-
tion of microtubules, causing starvation and death of the 
worm [8]. Tetrahydropyrimidines act as an agonist to the 
L-type nicotine acetylcholine gated ion channels, allow-
ing  Cl− to flow through, leading to depolarisation of mus-
cle cells and spastic paralysis of the parasite [9].
Overuse of anthelmintic drugs has contributed to 
the development of resistance in several parasites of 
veterinary importance [10]. The first reported case of 
anthelmintic resistance in Parascaris spp. was to the mac-
rocyclic lactone ivermectin in 2002 [11] and since then 
ivermectin resistance has been reported from around the 
world and is now considered widespread [12]. Resistance 
to the tetrahydropyrimidine pyrantel was first discov-
ered in the USA in 2008 [13] and has also been found in 
Australia [14] and, more recently, in Europe [3, 15]. The 
benzimidazole fenbendazole is generally effective against 
Parascaris spp. in Europe [3, 15], but sporadic cases of 
treatment failure have been reported from Australia [14] 
and Saudi Arabia [16]. Considering the risk of lethal com-
plications in foals infected with Parascaris spp. and the 
lack of new anthelmintic drugs for the equine market, the 
development of resistance to all available drug classes in 
Parascaris spp. is a major threat to equine health and the 
equine industry.
Despite the increasing problem of anthelmintic 
resistance, the underlying causes of the development of 
resistance in parasitic nematodes are still poorly under-
stood, particularly in ascarids. Advances in molecular 
techniques and genetics, such as the recent publica-
tion of a draft genome of P. univalens [17], have pro-
vided new possibilities to investigate responses in 
potential drug targets and pathways that may lead to 
resistance. There are several suggested mechanisms 
of anthelmintic resistance, including conformational 
changes or altered expression of the target molecule 
of the drug. Examples of conformational changes in 
the drug target are the three single nucleotide poly-
morphisms (SNPs) in the β-tubulin gene of strongyle 
nematodes. These mutations lead to amino acid substi-
tutions and have been associated with the loss of action 
of benzimidazoles, particularly in strongyle nematodes 
of veterinary importance [18–20]. Decreased sensitiv-
ity to macrocyclic lactones in Haemonchus contortus 
was suggested to be connected to SNPs in the GABA 
receptor subunit gene lgc-37 [21, 22], although this was 
challenged [23]. Additionally, reduced expression of the 
glutamate gated chloride channel avr-14 was described 
in ivermectin resistant isolates of Cooperia oncophora 
and Ostertagia ostertagi [24].
Other proposed mechanisms of anthelmintic resist-
ance include changes in drug metabolising enzymes 
and alterations in efflux pumps leading to inactiva-
tion or removal of the drugs [25]. Drug metabolism is 
usually divided into two phases; in phase I oxidation, 
reduction or hydrolysis convert the drug to a more reac-
tive compound that can be conjugated with an endog-
enous molecule such as glutathione or glucose in phase 
II. This results in a soluble, inactive drug that can be 
removed from the cell [26]. The phase I enzymes of the 
cytochrome P450-family (CYP) have been shown to 
be involved in drug resistance in insects [27], but the 
involvement of phase I and II enzymes in anthelmintic 
resistance of parasitic nematodes has not been thor-
oughly investigated, particularly not in ascarids. How-
ever, constitutively higher expression of a CYP34/35 
family member [28] as well as the phase II enzyme uri-
dine 5′-diphospho-glucuronosyltransferase-glucosyl-
transferase (UGT) [29] have been found in BZ resistant 
strains of H. contortus. Several studies have also shown 
evidence for upregulation of genes encoding drug efflux 
pumps, such as ATP-binding cassette (ABC) transport-
ers, in macrocyclic lactone resistant strongyle nema-
todes [30–32]. Taken together, these results indicate 
that changes in drug metabolism and efflux, play a role 
in anthelmintic resistance.
Despite anthelmintic resistance in P. univalens being a 
growing threat to equine health, little is known about the 
molecular mechanisms behind the development of resist-
ance. To our knowledge, no in vivo treatment experi-
ments have been performed in this parasite to date and 
only two studies have reported the expression of genes 
after in vitro drug exposure of adult Parascaris spp. [33, 
34].
The aim of our study was to identify genes that 
respond to drug treatment, focusing on drug tar-
gets, metabolising enzymes and transporters in adult 
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P. univalens. We have used a whole transcriptome 
approach to compare the gene expression after in vitro 
exposure to sub-lethal doses of ivermectin, pyrantel 
citrate and thiabendazole.
Methods
Parasite material and karyotype
Adult P. univalens were collected from the intestines of 
two Icelandic foals, approximately six months-old at an 
abattoir in Selfoss, Iceland. The horses originated from 
the same farm in southern Iceland and had never been 
treated with anthelmintic drugs. After removal from the 
intestine, worms were rinsed with 37 °C PBS (Life Tech-
nologies, Carlsbad, USA) and transported to the labo-
ratory (Institute for Experimental Pathology at Keldur, 
University of Iceland, Reykjavík, Iceland) in an insulated 
box. A faecal sample was taken from one of the foals for 
species identification by karyotyping of Parascaris spp. 
eggs as described in Martin et al. [3].
In vitro incubation experiment
To investigate the effect of in vitro incubation on viabil-
ity and gene expression, two groups of worms were used. 
One group of nine worms was divided into three con-
tainers containing cell culture media (RPMI-1640 with 
the addition of 10% foetal bovine serum, 1% penicillin/
streptomycin and 1% L-glutamine (Life Technologies, 
Carlsbad, USA) and then incubated for 24  h at 37  °C 
(control 24  h−DMSO). The other group of worms (n = 3) 
was immediately killed by removal of the anterior region 
upon arrival to the laboratory to serve as controls for the 
in vitro incubation (control 0 h) (Fig. 1).
In vitro drug exposure experiment
Worms were divided into three groups, one for each 
drug class. The worms were exposed to three different 
concentrations of ivermectin (IVM) (Sigma-Aldrich, 
Saint Louis, USA), pyrantel citrate (PYR) (Santa Cruz 
Biotechnology, Dallas, USA) or thiabendazole (TBZ) 
(Sigma-Aldrich), according to Table 1. The drug concen-
trations used were based on previous studies by Jans-
sen et  al. [34] for ivermectin exposure and Zhao et  al. 
[35] for pyrantel citrate and thiabendazole exposure. 
All anthelmintic drugs were dissolved in DMSO (Swed-
ish Veterinary Institute, Uppsala, Sweden) and serially 
diluted before addition to the media. For each concen-
tration, three biological replicates, each consisting of 
three worms, were divided into different containers con-
taining media and drug (final concentration of DMSO 
0.1%) and incubated at 37  °C for 24  h. An additional 
group of three worms, serving as control, was incubated 
in media with the addition of 0.1% DMSO (control 24 
 h+DMSO) (Table 1, Fig. 1).
Viability scoring and dissection
After 24  h incubation, worm viability was assessed 
according to the scoring system developed by Scare et al. 
[36] to evaluate the effects of the different drug concen-
trations on viability. The worms in each container were 
observed and viability scores between 2 (movement 
only when stimulated with forceps) and 6 (seven or 
more whole body movements without stimulation) were 
given for each container. One worm from each container 
(n = 3) was dissected and the anterior region, contain-
ing the pharynx and a small part of the anterior intes-
tine, was placed in individual tubes containing RNAlater 
(Ambion). Three worms were dissected directly upon 
arrival at the laboratory, serving as controls for the in 
vitro incubation experiment (control 0  h). The samples 
were then transported to Sweden (Swedish University 
of Agricultural Sciences, Department of Biomedical Sci-
ences and Veterinary Public Health, Division of Parasitol-
ogy) for the molecular analysis.
RNA extraction and sequencing
The samples were removed from RNAlater and cut into 
smaller pieces. One ml of Trizol (Invitrogen, Carls-
bad, USA) was added to each sample and the tissue was 
homogenized in a glass tissue grinder. After addition of 
0.2  ml of chloroform and centrifugation of the sample, 
100 µl of the upper aqueous phase was mixed with 350 µl 
lysis buffer from the NucleoSpin® RNA Plus Kit (Mach-
erey Nagel, Düren, Germany). RNA was then isolated 
according to the manufacturer’s instructions as described 
in the user manual of the kit. rDNase treatment and sub-
sequent clean-up (NucleoSpin RNA Clean-up, Macherey 
Nagel) was performed according to the manufacturer’s 
protocol to ensure RNA purity.
Sample preparation and sequencing were performed 
at SciLifeLab Uppsala, SNP&SEQ Technology Plat-
form. RNA concentration and integrity were checked by 
Fragment Analyzer (Agilent, Santa Clara, USA) before 
sequencing libraries were prepared from 500  ng total 
RNA using the TruSeq Stranded mRNA Library Prepa-
ration Kit including polyA selection (Illumina Inc., San 
Diego, USA) resulting in insert sizes of approximately 
140  bp. Three biological replicates per condition were 
sequenced using  Illumina NovaSeq S1 flow cells and 
100 bp paired end v1 sequencing chemistry, resulting in 
36 transcriptomes.
RNA‑seq analysis
Read quality assessment, adaptor removal, filtering 
and removal of duplicates was performed using fastp 
[37] (Pipeline with nextflow and docker support avail-
able at https ://githu b.com/SLUBi oinfo rmati csInf rastr 
uctur e/RNAse q_nf.). The resulting reads were mapped 
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against the predicted transcriptome of P. univalens 
(parascaris_univalens.PRJNA386823.WBPS11.mRNA_
transcripts.fa) available in WormBase ParaSite (https 
://paras ite.wormb ase.org/Paras caris _univa lens_prjna 
38682 3/Info/Index /) and transcripts were quantified 
using Salmon v.0.11.3 [38]. Transcript-level abundance, 
estimated counts and lengths from Salmon were sum-
marised together with gene-ids from the P. univalens 
transcriptome into matrices by the R package tximport 
[39] for downstream differential expression analysis. 
Genes with five or more read counts were included in 
the differential expression analysis performed by the R 
package DESeq2, v.1.22.2 [40]. P-values resulting from 
the Wald test incorporated into DESeq2 were adjusted 
for multiple testing using the Benjamini-Hochberg pro-
cedure [41] as applied by the R base p.adjust function. 
Genes with a log2 fold change of ≥ 1 or ≤ − 1 and an 
adjusted P-value < 0.05 were considered differentially 
expressed.
Fig. 1 Overview of study design. In the in vitro incubation experiment (a) three individual Parascaris univalens worms were sequenced for the 0 h 
control. For the Control 24 h−DMSO, nine worms were incubated in cell culture media in three containers (three worms per container). One worm 
from each container was used for RNA sequencing, in total three worms. In the in vitro drug exposure experiment (b), three worms were incubated 
in cell culture media containing 0.1% DMSO (Control 24 h+DMSO) and used for RNA sequencing. For each of the three anthelmintic substances 
ivermectin (IVM), pyrantel citrate (PYR) and thiabendazole (TBZ), three different concentrations of the drugs were used (see Table 1). For each 
concentration, three worms were incubated in each of three different containers, in total nine worms for every concentration. From each container, 
one worm was used for RNA sequencing, in total three worms for every concentration. In total 36 worms were sequenced in this study
Table 1 Samples included in the in vitro exposure experiment
Notes: Mean viability score of adult Parascaris univalens, number of differentially 
expressed genes (adjusted P < 0.05 and log2 fold change of ≥ 1 or ≤ − 1) and 
proportion of unknown differentially expressed genes after exposure to the 
anthelmintic drugs ivermectin (IVM), pyrantel citrate (PYR) and thiabendazole 
TBZ), at different concentrations for 24 h. The gene expression of drug-exposed 
worms was normalized to control 24  h+DMSO
Drug and concentration Viability Differentially 
expressed genes
Unknown 
genes (%)
IVM  10−9 M 3.5 256 44
IVM  10−11 M 4.5 119 44
IVM  10−13 M 6.0 177 46
PYR  10−6 M 3.0 38 50
PYR  10−8 M 4.5 191 45
PYR  10−10 M 6.0 84 50
TBZ  10−5 M 4.0 154 46
TBZ  10−7 M 5.0 46 43
TBZ  10−9 M 5.0 161 51
Control 24  h+ DMSO 6.0 – –
Page 5 of 14Martin et al. Parasites Vectors          (2020) 13:342  
For principal components analysis (PCA), gene 
counts were transformed into log2 scale by applying 
regularized logarithm approach using the rlog function 
provided in the DESeq2 package and plotted using the 
plotPCA function. For all the above analyses, R v.3.5.2 
was used [42]. Functional annotations of differentially 
expressed genes were identified by searching the pro-
tein sequences against the Swiss-Prot database [43] 
using BlastP (e-value ≤ 10−5). Candidate genes for drug 
metabolism and drug targets significantly differentially 
expressed after exposure to one or more drugs were 
identified by their orthologue name. To identify the 
number of genes common among the concentrations 
of a particular drug, gene IDs were used to construct 
comparative Venn diagrams using the venn.diagram 
function of the VennDiagram package in R v.3.6.1 [44]. 
Gene IDs corresponding to individual Venn diagram 
partitions were retrieved using the get.venn.partition 
function. Superfamilies of genes shared between con-
centrations were identified by BlastP searches (e-value 
≤ 10−6) in NCBI (https ://www.ncbi.nlm.nih.gov/).
Results
Karyotype
Parascaris univalens was identified in the karyotype as 
DAPI stained eggs from the first mitotic division showed 
one pair of chromosomes.
Viability after in vitro incubation
After 24 h incubation, all worms were alive irrespective 
of drug and concentration used for exposure. Control 
worms were highly viable (score 6), whereas worms incu-
bated in the highest drug concentrations were visibly less 
viable (score 3–4) than those incubated in lower concen-
trations (score 5–6) (Table 1).
Sequencing, quality control and mapping
RNA with RIN between 6.6–8.7 were sequenced on Illu-
mina Nova Seq. The number of reads per sample varied 
between 63–132 million after quality assessment and 
filtering by fastp. Sequences have been deposited in the 
European Nucleotide Archive (ENA) under the acces-
sion number PRJEB37010 (https ://www.ebi.ac.uk/ena). 
Mapping against the transcriptome resulted in an aver-
age mapping rate of 80–90% indicating high similar-
ity between the transcriptomic data and the reference 
transcriptome.
Analysis of differentially expressed genes
The number of differentially expressed genes for each 
drug concentration and the proportion of unchar-
acterised genes are shown in Table  1. The PCA plot 
illustrates the differences in gene expression between 
individual worms (Fig.  2). It should be noted that the 
largest difference in gene expression was observed 
between the non-incubated worms (control 0  h) and 
both control and drug-exposed worms that were incu-
bated in vitro for 24  h. Although care was taken to 
choose the largest worms (i.e. females) for the experi-
ment, it was discovered during the dissection that 
two individuals (IVM  10−11  M individual 2 and TBZ 
 10−5  M individual 1) lacked egg-containing uterus. 
These two individuals did not show up as outliers in 
the PCA plot (Fig.  2) and were therefore included in 
the analysis. Log2 fold change and adjusted P-values 
for the differentially expressed genes discussed in this 
article are listed in Additional file 1: Table S1.
Transcriptional response in control worms after in vitro 
incubation
The largest number of differentially expressed genes 
was seen in the in vitro incubation experiment, where 
unexposed worms incubated in media (control 24  h−
DMSO) were compared to non-incubated worms (control 
0 h). Between these two groups, 1061 genes were differ-
entially expressed and interestingly, among these were a 
number of candidate genes putatively involved in drug 
metabolism, such as CYPs, flavin containing monooxy-
genase (FMO), short chain dehydrogenase/reductase 
(SDR), glutathione S-transferase (GST) and UGTs, as 
well as ABC-transporters (Additional file  2: Table  S2). 
Forty percent of the differentially expressed genes were 
uncharacterised.
Differential expression of putative drug targets
Putative drug targets were identified by their anno-
tation and orthologue. Transcripts of ten drug tar-
gets were differentially expressed in worms exposed 
to IVM, PYR or TBZ compared to control 24  h+DMSO 
(Fig.  3a). An orthologue to the GABA-receptor subu-
nit lgc-37 in H. contortus (GenBank: X73584), tran-
script PgR047_g061, was upregulated after exposure 
to the highest concentration of IVM  (10−9  M). Three 
transcripts orthologous to acetylcholine receptor 
subunits (AChRs); PgB02X_g213, PgR034_g017 and 
PgR034_g018, were upregulated, whereas five AChRs; 
PgR043_g026, PgR075_g041, PgR005X_g207, PgR006_
g054 and PgR045_g040, were downregulated accord-
ing to Fig.  3a. The transcript PgE153_g002, identical 
to the previously described P. equorum β-tubulin iso-
type 2 (GenBank: KC713798), was downregulated after 
exposure to the highest dose of TBZ  (10−5 M) but also 
after exposure to IVM  (10−11 M) and PYR  (10−8 M and 
 10−10 M) (Fig. 3a).
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Comparison of the transcriptional response after exposure 
to different concentrations of IVM, PYR or TBZ
The ten most upregulated and downregulated genes after 
exposure to each drug are shown in Table 2. Of the most 
upregulated genes across all drugs, 57% are uncharacter-
ized and only one transcript, the GABA-receptor subunit 
PgR047_ g061 (lgc-37), has previously been described as 
a drug target to IVM and to be involved in anthelmintic 
resistance. Of the most downregulated genes after expo-
sure to the three different drugs, 53% are uncharacterized 
and two transcripts, the acetylcholine receptor PgR005X_
g207 and the B-tubulin isotype 2 gene PgE153_g002, are 
previously described as drug targets of PYR and TBZ. No 
genes previously described to be involved in drug metab-
olism were found in this list.
Differentially expressed genes shared among the three 
concentrations of each drug are visualized in Fig. 4 and 
Table  3. After IVM exposure, 14 transcripts showed 
overlapping differential expression for all three concen-
trations (Fig. 4a). Of these, nine transcripts were upregu-
lated whereas five were downregulated. The differentially 
expressed genes included four transcripts belonging 
to the SDR superfamily, putatively involved in phase 
I metabolism, two transcripts of the major facilitator 
superfamily (MFS), known to be involved in drug efflux 
and resistance in bacteria and yeast, and one transcript 
of the solute carrier superfamily (SCS), involved in trans-
portation. Of the remaining seven differentially expressed 
transcripts, three do not have any known connection to 
drug metabolism or transport, while four transcripts are 
uncharacterised (Table 3).
After exposure to PYR, ten transcripts were commonly 
differentially expressed (Fig.  4b) and all but one were 
downregulated. As in the IVM exposed worms, the tran-
script PgR006_g137, a member of MFS, was downregu-
lated (Table 3). Of the remaining differentially expressed 
transcripts, four belong to superfamilies not connected 
to drug metabolism or transportation, whereas five tran-
scripts are uncharacterised (Table 3).
Six transcripts were commonly differentially expressed 
after exposure to all three concentrations of TBZ 
(Fig.  4c), five downregulated and one upregulated. Of 
these, two transcripts are involved in processes not con-
nected to drug metabolism or transport, while four are 
uncharacterised or not similar to any known superfamily 
(Table 3).
Fig. 2 Principal components analysis plot showing the clustering of adult Parascaris univalens incubated in the presence of the anthelmintic 
drugs ivermectin (IVM), pyrantel citrate (PYR) and thiabendazole (TBZ) at different concentrations, as well as control worms. The largest variation in 
gene expression was observed between the non-incubated worms (control 0 h) and all worms incubated in vitro. Each symbol corresponds to an 
individual worm
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Differential expression of other putative candidate genes
Putative candidate genes involved in drug metabolism 
were identified by their annotation and orthologue. 
Transcripts of 12 metabolising genes involved in phase 
I and phase II drug metabolism were identified in 
worms exposed to all drugs (Fig. 3b).
Four phase I transcripts were differentially expressed 
after drug exposure. One transcript belonging to 
the CYP family (PgR020_g037) was downregulated 
after exposure to the medium concentration of IVM 
 (10−11  M). Three transcripts belonging to the flavin 
containing monooxygenase (FMO) superfamily were 
differentially expressed in an inconsistent pattern 
after drug exposure. The transcript PgR003_g196 was 
downregulated after exposure to IVM  (10−9  M), TBZ 
 (10−5  M) and PYR  (10−10  M). The transcript PgR016_
g066 was upregulated after exposure to IVM  (10−9 M) 
only, whereas the transcript PgR161_g008 was upregu-
lated after exposure to PYR  (10−8 M) and TBZ  (10−9 M) 
(Fig. 3b).
Eight genes belonging to two superfamilies of the phase 
II metabolizing pathway were also differentially expressed 
in an inconsistent pattern irrespective of drug and con-
centration used (Fig.  3b). One transcript, PgR024_g121, 
of the glutatione S-transferase superfamily (GST), was 
down regulated, but only after exposure to the lowest 
concentration of IVM  (10−13 M). Seven transcripts of the 
uridine 5′-diphospho-glucuronosyltransferase superfam-
ily (UGT) were downregulated in an unspecific pattern 
after exposure to all drugs (Fig. 3b).
Discussion
The equine roundworm Parascaris spp. is resistant to 
several classes of anthelmintic drugs, but regardless of 
this, few studies focusing on the mechanisms involved 
have been published [33, 34, 45]. In this study, the 
transcriptomes of 36 individual P. univalens worms, 
confirmed by karyotyping, were analysed after in vitro 
exposure to different concentrations of IVM, PYR and 
TBZ. We found, to our knowledge for the first time 
in ascarid worms, that the expression of phase I gene 
families SDR and FMO were affected by exposure to 
anthelmintic drugs. We also found a 250-fold upregula-
tion of a GABA receptor subunit.
The GABA receptor subunit PgR047_g061, orthol-
ogous to the H. contortus gene lgc-37, was upregu-
lated after exposure to the highest IVM concentration 
 (10−9 M) (Fig. 3). GABA receptors are targets for IVM in 
Fig. 3 Heat map showing the differential expression of genes coding for putative drug targets (a) and genes coding for putative phase I and 
phase II metabolizing enzymes (b) after in vitro exposure of Parascaris univalens to the anthelmintic drugs ivermectin (IVM), pyrantel citrate (PYR) 
and thiabendazole (TBZ) at different concentrations. Genes with a log2 fold change of ≥ 1 or ≤ − 1 and an adjusted P-value (Walds test and 
Benjamini-Hochberg procedure) < 0.05 were considered differentially expressed
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Table 2 The 10 most up- and downregulated genes (adjusted P-value < 0.05) in Parascaris univalens worms exposed to three different 
concentrations of the anthelmintic drugs ivermectin (IVM), pyrantel citrate (PYR) and thiabendazole (TBZ) for 24 h
Gene ID Log2FC Orthologue Condition
PgR001X_g190 23.45 Uncharacterised IVM  10−9 M
PgR013_g129 8.93 RPE Ribulose-phosphate 3-epimerase IVM  10−13 M
PgR047_g061 8.23 GABRA6 Gamma-aminobutyric acid receptor subunit alpha-6 IVM  10−9 M
PgB04_g079 6.77 RPL3 60S ribosomal protein L3 IVM  10−13 M
PgR010_g071 5.77 Uncharacterised IVM  10−9 M
PgR152_g010 5.36 COL9A1 Collagen alpha-1(IX) chain IVM  10−11 M
PgR045_g001 5.32 Uncharacterised IVM  10−9 M
PgR004_g064 4.85 Uncharacterised IVM  10−13 M
PgR001X_g079 4.35 Uncharacterised IVM  10−9 M
PgB05_g040 4.30 Uncharacterised IVM  10−13 M
PgB04_g079 9.10/5.51 RPL3 60S ribosomal protein L3 PYR  10−6 M/PYR  10−10 M
PgE230_g001 8.25 Uncharacterised PYR  10−6 M
PgR020_g019 6.13 Uncharacterised PYR  10−10 M
PgR004_g204 5.88 Uncharacterised PYR  10−8 M
PgR152_g010 5.67 COL9A1 Collagen alpha-1(IX) chain PYR  10−6 M
PgR001X_g079 5.01 Uncharacterised PYR  10−8 M
PgR099_g042 4.80 hpo-4 Putative GPI-anchor transamidase PYR  10−8 M
PgE192_g001 3.71 Uncharacterised PYR  10−8 M
PgR002_g035 3.63 ani-2 Anillin-like protein 2 PYR  10−6 M
PgR123_g005 3.48 Pym Partner of Y14 and mago PYR  10−8 M
PgR307_g002 12.41/11.44 EDF1 Endothelial differentiation-related factor 1 homolog TBZ  10−9 M/TBZ  10−5 M
PgR256X_g003 8.82 Uncharacterised TBZ  10−9 M
PgR010_g071 8.22 Uncharacterised TBZ  10−9 M
PgR190X_g006 8.03 Uncharacterised TBZ  10−9 M
PgR001X_g019 7.85 Uncharacterised TBZ  10−7 M
PgR152_g010 7.15 COL9A1 Collagen alpha-1(IX) chain TBZ  10−5 M
PgB04_g079 6.49 RPL3 60S ribosomal protein L3 TBZ  10−9 M
PgR034_g082 6.33 Uncharacterised TBZ  10−9 M
PgR099_g042 5.01 hpo-4 Putative GPI-anchor transamidase TBZ  10−7 M
PgR001X_g079 4.76 Uncharacterised TBZ  10−9 M
PgR166_g010 − 7.80/− 5.92 agmo-1 alkylglycerol monooxygenase IVM  10−13 M/IVM  10−9 M
PgR049_g007 − 7.50 Uncharacterised IVM  10−13 M
PgE193_g002 − 6.88 cyb-3 G2/mitotic-specific cyclin-B3 IVM  10−9 M
PgR260_g001 − 6.74 Eif4a3 Eukaryotic initiation factor 4A-III IVM  10−9 M
PgR005X_g207 − 6.28 cup-4 Acetylcholine receptor-like protein cup-4 IVM  10−13 M
PgE182_g003 − 6.11 ZFP36 mRNA decay activator protein IVM  10−9 M
PgR002_g265 − 6.02 Uncharacterised IVM  10−9 M
PgR022X_g031 − 5.72 Uncharacterised IVM  10−13 M
PgB32_g014 − 5.71 Uncharacterised IVM  10−9 M
PgE068_g001 − 5.70 Uncharacterised IVM  10−9 M
PgR022X_g031 − 8.43 Uncharacterised PYR  10−6 M
PgB08_g035 − 8.13 ZC116.3 Probable cubilin PYR  10−8 M
PgR389_g001 − 7.93 Uncharacterised PYR  10−8 M
PgR005X_g207 − 7.90 cup-4 Acetylcholine receptor-like protein cup-4 PYR  10−6 M
PgR049_g007 − 7.84 Uncharacterised PYR  10−10 M
PgB22_g038 − 6.34 F01G4.6 Phosphate carrier protein, mitochondrial PYR  10−10 M
PgR022X_g030 − 5.72 Uncharacterised PYR  10−6 M
PgB08_g034 − 5.65 ZC116.3 Probable cubilin PYR  10−6 M
PgR166_g010 − 5.57 agmo-1 Alkylglycerol monooxygenase PYR  10−8 M
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nematodes, but generally show lower affinity to the drug 
than the glutamate receptors [22]. Even so, mutations 
in lgc-37 have been found to decrease the sensitivity of 
macrocyclic lactone drugs in H. contortus [21] suggesting 
a role in resistance. Transcriptional regulation of lgc-37 
(PgR047_g061) in association with IVM response has not 
been reported previously, but taken together these results 
indicate that this gene could be an interesting candidate 
for further research in P. univalens.
Eight transcripts orthologous to AChR subunits, 
the putative drug target for PYR, were differentially 
expressed, but with no clear pattern after exposure to 
IVM, PYR and TBZ. Since the L-subtypes of AChRs have 
not yet been characterized in Parascaris spp., we cannot 
conclude whether these transcripts are the drug targets 
for pyrantel. Previous studies have shown that truncated 
forms of AChRs, as well as reduced expression of AChR 
subunits, have been associated with decreased sensitivity 
to PYR in strongyle nematodes [46, 47].
Furthermore, β-tubulin isotype 2 was downregulated 
after exposure to all three drug classes, however to a 
higher degree after TBZ exposure than after exposure 
to IVM or PYR. So far only two β-tubulin isotypes (iso-
type 1 and 2) have been described in Parascaris spp. 
[48], though more might be present in the genome 
since six putative β-tubulin genes were found in the 
closely related parasite Ascaridia galli [49]. It has also 
been mentioned that the Ascaris suum genome con-
tains at least nine β-tubulin genes [50]. It should be 
noted that the isoforms of ascarid β-tubulins should 
not be directly compared to the strongyle nematodes 
as phylogenetic studies have shown that they are evo-
lutionary separated [48, 49]. In a study by Martis et al. 
[49], where the transcriptomes of A. galli were com-
pared before and after in vivo exposure to flubendazole, 
Table 2 (continued)
Gene ID Log2FC Orthologue Condition
PgR057_g068 − 5.51 Uncharacterised PYR  10−10 M
PgR012_g016 − 13.72 Uncharacterised TBZ  10−9 M
PgR049_g007 − 9.59/− 8.19 Uncharacterised TBZ  10−7 M/TBZ  10−9 M
PgR004_g249 − 8.12 rps28 40S ribosomal protein S28 TBZ  10−7 M
PgB15_g052 − 6.84 Uncharacterised TBZ  10−9 M
PgE153_g002 − 6.84 Tubulin beta-1 chain TBZ  10−5 M
PgR022X_g030 − 6.83 Uncharacterised TBZ  10−9 M
PgR011_g087 − 6.76 Uncharacterised TBZ  10−9 M
PgE193_g002 − 6.70 cyb-3 G2/mitotic-specific cyclin-B3 TBZ  10−5 M
PgR022X_g031 − 6.46 Uncharacterised TBZ  10−9 M
PgR005X_g207 − 6.32 cup-4 Acetylcholine receptor-like protein cup-4 TBZ  10−7 M
Fig. 4 Venn diagrams showing the number of differentially expressed genes unique to and shared among Parascaris univalens worms exposed to 
three different concentrations of the anthelmintic drugs ivermectin (a), pyrantel citrate (b) and thiabendazole (c). Genes with a log2 fold change of 
≥ 1 or ≤ − 1 and an adjusted P-value (Walds test and Benjamini-Hochberg procedure) < 0.05 were considered differentially expressed
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no differential expression of β-tubulins was found, 
whereas a study by Tyden et al. [51] showed an upreg-
ulation of β-tubulin isotype 1 in Parascaris spp. eggs 
exposed to thiabendazole during embryogenesis. How-
ever, downregulation of specific isotypes of β-tubulins 
has been observed in human cancer cells resistant to 
microtubule destabilising drugs [52, 53], indicating that 
expressional regulation of β-tubulin could be a cellular 
response to certain drugs.
Comparing the differential expression after exposure to 
three different drugs provided valuable insights on how 
expression of putative drug targets are similarly affected 
regardless of the drug used. Another point to consider is 
the inconsistent expression of putative drug targets and 
metabolising enzymes across the different concentrations 
of a drug. This could be explained by individual variation 
in gene expression between the biological replicates or 
can be an effect of changes in gene expression from drug 
metabolism to severe stress or apoptosis in response to 
Table 3 Differentially expressed genes (log2 fold change ≥ 1 or ≤ − 1 and adjusted P-value < 0.05) and their corresponding 
superfamilies shared among Parascaris univalens worms exposed to three different concentrations of the anthelmintic drugs 
ivermectin (IVM), pyrantel citrate (PYR) and thiabendazole (TBZ) for 24 h
Note: The gene expression of drug-exposed worms was normalized to control 24  h+ DMSO
Gene ID Superfamily Log2FC
Ivermectin Concentration 10−9 M 10−11 M 10−13 M
PgB01_g106 Short-chain dehydrogenases/reductases (SDR) cl25409 − 1.05 − 1.57 − 1.50
PgR004_g112 Short-chain dehydrogenases/reductases (SDR) cl25409 1.94 1.94 1.27
PgR007_g080 Short-chain dehydrogenases/reductases (SDR) cl25409 1.92 1.75 1.80
PgR127_g021 Short-chain dehydrogenases/reductases (SDR) cl25409 1.54 1.50 1.36
PgR006_g137 The major facilitator superfamily (MFS) cl28910 − 1.12 − 1.39 − 1.92
PgR015_g078 The major facilitator superfamily (MFS) cl28910 2.32 2.11 2.44
PgR011_g039 Solute carrier families 5 and 6-like superfamily (SLC) cl00456 1.15 1.29 1.47
PgR135_g007 C-type lectin (CTL) cl02432 1.06 1.29 1.28
PgR422_g001 RNA recognition motif (RRM) superfamily cl17169 1.62 1.63 1.99
PgR037_g063 Clc-like superfamily cl06205 1.72 1.84 1.39
PgB06_g058 No conserved domains detected 1.69 1.77 2.51
PgR061_g018 No conserved domains detected − 1.55 − 1.84 − 2.14
PgR142_g012 No conserved domains detected − 2.15 − 1.26 − 1.53
PgR011_g030 No conserved domains detected − 1.04 − 1.40 − 1.79
Pyrantel Concentration 10−6 M 10−8 M 10−10 M
PgR006_g137 Major facilitator superfamily 
cl28910
− 1.97 − 1.88 − 1.70
PgB08_g086 Alpha/beta hydrolases cl21494 − 3.89 − 4.04 − 2.64
PgB27X_g004 C-type lectin (CTL) cl02432 − 3.11 − 4.46 − 2.05
PgR050X_g009 Olfactomedin-like domain cl02549 − 3.20 − 3.62 − 1.62
PgB08_g034 CUB domain cl00049 − 5.65 − 4.90 − 1.13
PgE206_g001 No conserved domains detected − 2.88 − 3.92 − 3.08
PgR022X_g030 No conserved domains detected − 5.72 − 5.15 − 2.92
PgR022X_g031 No conserved domains detected − 8.43 − 4.43 − 2.23
PgR093_g009 No conserved domains detected − 4.87 − 4.88 − 2.64
PgR186_g008 No conserved domains detected 1.05 1.82 1.51
Thiabendazole Concentration 10−5 M 10−7 M 10−9 M
PgB08_g034 CUB domain cl00049 − 2.82 − 3.52 − 5.09
PgR004_g040 Carbonic anhydrase alpha 
(vertebrate-like) group cl00012
− 1.70 − 3.65 − 1.91
PgE192_g001 No conserved domains detected 1.30 3.48 2.17
PgR004_g250 No conserved domains detected − 1.50 − 1.73 − 1.81
PgR022X_g030 No conserved domains detected − 4.64 − 5.65 − 6.83
PgR049_g007 No conserved domains detected − 6.11 − 9.59 − 8.19
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high doses of anthelmintics. These are important findings 
to consider in the analysis of expression data and, to our 
knowledge, this is the first time this has been shown in P. 
univalens.
Several members of the phase I superfamily SDR were 
found to be differentially expressed after drug exposure in 
our study. The SDR family is a large superfamily present 
in all life forms [54], containing enzymes with conserved 
structure that metabolise endogenous and xenobiotic 
compounds by phase I reduction [55, 56]. Upregulation 
of SDR enzymes is believed to contribute to resistance 
towards chemotherapeutic agents in cancer treatment in 
human medicine [57] and has also been seen in Caeno-
rhabditis elegans after in vitro exposure to benzimidazole 
drugs [58]. The involvement of SDR in drug metabolism 
in parasitic nematodes is largely unknown. It has been 
shown that reduction is the main metabolic pathway for 
flubendazole metabolism in H. contortus, though it has 
not been established if the enzymes involved belonged 
to the SDR family or other related superfamilies [59]. In 
summary, members of the SDR family may participate in 
the xenobiotic metabolism in helminths, but their possi-
ble involvement in anthelmintic resistance has not been 
studied in parasitic nematodes.
Members of the FMO family are phase I enzymes 
known to be involved in the biotransformation of xeno-
biotic compounds in many phyla [60]. FMO enzymes 
have been shown to play a role in albendazole metabo-
lism in the common liver fluke Fasciola hepatica and 
to be involved in the resistance to this drug [61, 62]. In 
contrast, Vokřál et  al. [63] did not observe any activity 
of FMO enzymes in H. contortus in response to alben-
dazole. In our study, two transcripts of the FMO family 
were upregulated after exposure to all drugs, indicating 
that they may play a universal role in the drug metabo-
lism in P. univalens.
Only one member of the CYP family (PgR020_g037) 
was differentially expressed in this study, with a down-
regulation after exposure to IVM  (10−11 M). This finding 
is in contrast to the upregulation of the CYP family mem-
ber PgR071_g005 in P. univalens in vitro exposed to IVM 
and oxibendazole [33]. Upregulation of CYP genes has 
also been observed in susceptible strains of H. contortus 
after in vitro exposure to IVM [26].
In summary, we found that several phase I enzymes 
were differentially expressed in P. univalens after drug 
exposure. To our knowledge, SDR and FMO enzymes 
have not yet been characterized in parasitic helminths 
and therefore their roles in drug metabolism or anthel-
mintic resistance have not been investigated. Although 
no consistent pattern was observed regardless of drug 
and concentration used, we found downregulation 
of several members of the phase II enzymes of the 
UGT family. In contrast, several studies have shown 
an increased expression and activity of UGTs in ben-
zimidazole-resistant strains of H. contortus [29, 63]. 
Although the expression and function of phase I and 
phase II enzymes have been investigated in parasitic 
helminths, few studies have focused on ascarid worms 
and thus further investigation is required.
The upregulation of genes encoding transporters and 
drug efflux pumps have been suggested as a mecha-
nism behind multidrug resistance in parasitic worms 
[30–32]. Focus has so far been mainly on certain ABC-
transporters genes, but in agreement with Janssen et al. 
[34], we did not observe any changes in gene expres-
sion of pgp-11 and pgp-16 after drug exposure. On 
the other hand, we found that transcripts of the trans-
portation superfamilies MFS and SCS were differen-
tially expressed after exposure to anthelmintic drugs. 
These are large superfamilies of membrane proteins 
present in both prokaryotes and eukaryotes, trans-
porting endogenous substances and drugs across cell 
membranes [64, 65]. The role of MFS proteins in drug 
resistance in parasitic helminths has so far not been 
investigated. However, their involvement in resistance 
to specific drugs, as well as multidrug resistance in bac-
teria and yeast, are well studied [64], indicating that 
these could be interesting candidates to investigate fur-
ther in regards to anthelmintic resistance.
Among the ten most upregulated and downregulated 
genes after exposure to each of the three drugs, there 
were no previously described genes encoding xenobi-
otic enzymes or transporters. Even though the function 
of more than 50% of these genes is unknown, this list 
might contain novel candidates for drug metabolism 
and needs to be further investigated.
In a recently published study, Scare et al. [33] studied 
the transcriptomes of adult P. univalens after in vitro 
exposure to ivermectin and oxibendazole. Genes iden-
tified as potentially involved in drug detoxification and 
regulatory mechanisms differed from our results with 
only one similarity between the two studies, a member 
of the CYP family. These varying results are most likely 
due to the differences in study design between the two 
experiments, such as different drug concentrations and 
drug exposure times and the use of different tissues 
for RNA extraction. Scare et al. [33] also allowed a 24 
h acclimatization period for the worms in tissue cul-
ture media before drug exposure, whereas we started 
the drug exposure at 0 h. These two studies show that 
despite similar aims, experimental design can affect 
differential expression considerably and thus also high-
light the potential for future studies to identify impor-
tant genes involved in drug interactions not found in 
either study.
Page 12 of 14Martin et al. Parasites Vectors          (2020) 13:342 
In our experiment, unexposed control worms (con-
trol 24  h−DMSO) were not visibly affected by incuba-
tion at 37  °C for 24   h. Even so, we observed a large 
number (n = 1061) of differentially expressed genes in 
these worms when compared to non-incubated worms 
(control 0 h). Among these genes were several can-
didates putatively involved in drug metabolism and 
efflux. This implies that although not visibly affected 
by the in vitro incubation, the worms become stressed 
from the change in environment and nutritional sup-
ply when removed from the host intestine to incuba-
tion in media. This is an important point to consider 
when performing in vitro experiments. Although we 
cannot be sure that the in vitro response to drug treat-
ment reflects what would happen in a similar in vivo 
situation, it is a way to obtain more knowledge about 
the parasite response to drug exposure. Since whole 
live animal experiments in foals are both expensive and 
pose ethical dilemmas, further development of in vitro 
models is crucial for research in parasitic nematodes.
Conclusions
We have explored the changes in gene expression across 
the complete transcriptome of adult P. univalens in 
response to in vitro exposure of the anthelmintic drugs 
ivermectin, pyrantel citrate and thiabendazole. We found 
a 250-fold upregulation of a possible target of ivermec-
tin, an orthologue to the GABA receptor subunit lgc-37, 
which is an interesting candidate gene to investigate fur-
ther. Surprisingly, few other candidate genes found in 
other parasitic worms, such as P-gps, were differentially 
expressed in our experiment. However, our data revealed 
differential expression of several novel gene candidates 
belonging to the phase I superfamilies SDR and FMO, as 
well as transporters belonging to the MFS and SLC fami-
lies. To our knowledge, this is the first time the expres-
sion of these genes has been described in P. univalens and 
future work should be focused on characterising these 
candidate genes further to explore their potential involve-
ment in drug metabolism and anthelmintic resistance.
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